EMA approval of lenalidomide plus rituximab for adult patients with R/R FL

The Lymphoma Hub has recently covered news on the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use, issuing a positive opinion for the approval of lenalidomide plus rituximab (R2) as a treatment for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). You can read it here.

On the 20th of December 2019, the R2 combination was approved by the EMA, based on the positive data from multi-center phase III studies AUGMENT (NCT01938001) and MAGNIFY (NCT01996865).1 

You can read the Lymphoma Hub’s coverage of the AUGMENT study, watch an interview with Marek Trněný discussing the post-hoc analysis of the data in the elderly population, and Mathias Rummel discussing the MAGNIFY trial.

  1. Bristol-Myers Squibb. Bristol-Myers Squibb receives European Commission approval for Revlimid® (lenalidomide) in combination with rituximab for the treatment of adult patients with previously treated follicular lymphoma. December 20, 2019. https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-receives-european-commission-approval-rev. Published; December 20, 2019, [Accessed January 3 2020]
Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF